The Valley Desk

ArticleFrontiers in oncologyPublished

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University Hospital, with Jefferson Health linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Frontiers in oncology
Published
Subject terms
Treatment; Diffuse Large B Cell Lymphoma; Front-line; R-chop; Polatuzumab Vedotin
PubMed ID
36686842
PubMed Central ID
PMC9851376
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal